ERBB2 and colorectal carcinoma: GENIE consortium data published in 2017 have exhibited that ERBB2 is altered in 4.69% of 2,081 CRC patients with R678Q and V842I present in 0.48% and 0.38% of all CRC patients, respectively (41).